We have observed
9 EP applications
has served for within the last five+ years.
(We consider all applications which have an EP A1 or A2 publication dated after March 24, 2014).
Please note, that we only count EP applications,
in which the name of the patent attorney is explicitly mentioned as representative.
These EP applications are:
Selective local inhibition of TNFR1-mediated functions at the site of antigen/allergen presentation
Reactor with electroluminescence particles in the reaction medium
Method for pneumatic manipulation of a concrete component
Induction of antigen-specific tolerance by peripheral phagocytosis
HIGH BREAKDOWN VOLTAGE DIODE AND METHOD OF FORMING SAME
POLYMER LAYER COMPOSITE FOR A SECURITY AND/OR VALUABLE DOCUMENT
Method for the identification of transiently Foxp3 negative regulatory T-cells from human peripheral blood
ANTIGEN-SPECIFIC IMMUNOTHERAPY USING TOLERIZING LIPOSOMES
FLOOR SOCKET CONNECTION